HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection.

AIDS. 1998 Aug 20;12(12):1491-4. Unique Identifier : AIDSLINE MED/98394553
Woods ML 2nd; MacGinley R; Eisen DP; Allworth AM; Infectious Diseases Unit, Wattlebrae, Royal Brisbane Hospital,; Herston, Queensland, Australia.

Abstract: OBJECTIVE: To describe two cases of cryptococcal meningitis and one re-exacerbation of Cryptococcus-associated meningitis occurring in temporal association with commencement of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection (CD4 cells < 50 x 10(6)/l), which suggests that partial immune restitution can facilitate development of clinically apparent meningitis in response to Cryptococcus or its antigen. DESIGN: All HIV-infected patients with culture-proven cryptococcal meningitis diagnosed at a tertiary referral centre specialist infectious diseases unit from 1 January 1996 to 31 December 1996 were reviewed to examine the clinical and immunological parameters prior to and after commencing antiretroviral therapy. RESULTS: Three patients were diagnosed with clinically apparent meningitis within 7-39 days of changing or altering antiretroviral combination therapy consisting of zidovudine or stavudine, in combination with lamivudine and saquinavir. All patients had CD4 cell counts below 50 x 10(6)/l at initiation of therapy. Following institution of HAART, evidence of immune restitution was suggested by the following: (i) significant increases (3.7-14-fold) in numbers of CD4 cells (all three patients), (ii) significantly reduced (> 2-4 log10 reduction) HIV viral loads (two out of three patients), and (iii) prominent inflammatory changes in cerebrospinal fluid (white blood cells > 10 x 10(6)/l) at diagnosis (two out of three patients). CONCLUSIONS: Our report suggests that in patients with advanced HIV infection, partial immune restitution induced by HAART can precipitate onset of clinically apparent meningitis in those patients with latent cryptococcal central nervous system infection or with residual cryptococcal antigen present in the cerebrospinal fluid.

Keywords: JOURNAL ARTICLE Anti-HIV Agents/ADVERSE EFFECTS/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/DIAGNOSIS/*IMMUNOLOGY/ PATHOLOGY Case Report Cerebrospinal Fluid/MICROBIOLOGY Cryptococcosis/DIAGNOSIS/*IMMUNOLOGY/PATHOLOGY Cryptococcus/ISOLATION & PURIF CD4 Lymphocyte Count Drug Therapy, Combination Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY Meningitis, Fungal/DIAGNOSIS/*IMMUNOLOGY/PATHOLOGY
990130
A9911032

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .